{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T07:11:58Z","timestamp":1724137918464},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Peripherally acting \u03bc-opioid receptor antagonists (PAMORAs) are indicated to treat laxative-refractory opioid-induced constipation (OIC). While several PAMORAs exist, no head-to-head comparative data are available. This study evaluated the efficacy, safety, and cost of oral naloxegol vs subcutaneous methylnaltrexone for OIC in the hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter retrospective chart review, patients who received oral naloxegol or subcutaneous methylnaltrexone as an inpatient were included if they were at least 18 years old, were still admitted to the hospital 48 hours after the first PAMORA dose, and either had an outpatient opioid prescription or received at least 30 morphine milligram equivalents in the 24 hours before the first PAMORA dose. The primary outcome was achievement of a bowel movement (BM) within 48 hours of the first dose. Secondary outcomes included a BM in 24 hours, time to the first BM, antimotility agent use, PAMORA cost per patient, and use of a second PAMORA due to failure of the first agent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 330 patients were included with 2:1 allocation (220 patients receiving methylnaltrexone vs 110 patients receiving naloxegol). Baseline characteristics were similar between the groups, except for body mass index and weight. Naloxegol met a prespecified noninferiority margin of 15% in production of a BM within 48 hours (risk difference, \u20134.6%; 90% confidence interval, \u201313.6% to 4.5%; P = 0.028). Achievement of a BM within 24 hours and time to first BM were also noninferior. Antimotility agent use was higher with naloxegol, naloxegol cost $193.16 less per patient, and 2 patients switched from naloxegol to methylnaltrexone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Oral naloxegol may be an effective, cost-efficient alternative to subcutaneous methylnaltrexone for treatment of OIC in the hospital setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac356","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T13:31:17Z","timestamp":1669642277000},"page":"S70-S76","source":"Crossref","is-referenced-by-count":3,"title":["Impact of oral naloxegol vs subcutaneous methylnaltrexone in treatment of opioid-induced constipation in the hospital setting"],"prefix":"10.1093","volume":"80","author":[{"given":"Ricki","family":"Nero","sequence":"first","affiliation":[{"name":"Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center , Lebanon, NH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Allen","sequence":"additional","affiliation":[{"name":"Ascension St. Vincent\u2019s Riverside , Jacksonville, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirubel","family":"Hailu","sequence":"additional","affiliation":[{"name":"Ascension St. Vincent\u2019s Riverside , Jacksonville, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refat","family":"Noor","sequence":"additional","affiliation":[{"name":"Ascension St. Vincent\u2019s Riverside , Jacksonville, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Theiss","sequence":"additional","affiliation":[{"name":"Ascension St. Vincent\u2019s Riverside , Jacksonville, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"369","key":"2023061509163281100_CIT0001","first-page":"1","article-title":"Prevalence of prescription pain medication use among adults: United States, 2015-2018","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"4","key":"2023061509163281100_CIT0002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1756283X15578608","article-title":"Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities","volume":"8","author":"Nelson","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"2023061509163281100_CIT0003","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced constipation","volume":"36","author":"Argoff","year":"2020","journal-title":"Clin J Pain"},{"issue":"2","key":"2023061509163281100_CIT0004","first-page":"93","article-title":"Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain","volume":"8","author":"Wan","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"2023061509163281100_CIT0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"2023061509163281100_CIT0006","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/CEOR.S61602","article-title":"Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review","volume":"6","author":"Coyne","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"key":"2023061509163281100_CIT0007","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2147\/DDDT.S221278","article-title":"The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety","volume":"14","author":"Pergolizzi","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2023061509163281100_CIT0008","author":"Food and Drug Administration"},{"key":"2023061509163281100_CIT0009","volume-title":"SAS OnDemand for Academics: User\u2019s Guide","author":"SAS Institute","year":"2021"},{"key":"2023061509163281100_CIT0010","article-title":"Naloxegol.","volume-title":"Lexicomp Online [proprietary data]","year":"2022"},{"key":"2023061509163281100_CIT0011","article-title":"Methylnaltrexone.","volume-title":"Lexicomp Online [proprietary data]","year":"2022"},{"issue":"5","key":"2023061509163281100_CIT0012","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jpainsymman.2006.12.018","article-title":"Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review","volume":"34","author":"Becker","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"2023061509163281100_CIT0013","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1526-4637.2007.00335.x","article-title":"Efficacy and safety of \u03bc-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"McNicol","year":"2008","journal-title":"Pain Med"},{"issue":"3","key":"2023061509163281100_CIT0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1060028016677310","article-title":"Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit","volume":"51","author":"Merchan","year":"2017","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac356\/48757212\/zxac356.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/Supplement_2\/S70\/50613938\/zxac356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/Supplement_2\/S70\/50613938\/zxac356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:17:57Z","timestamp":1686820677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/Supplement_2\/S70\/6849536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":14,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,11,28]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac356","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,11,28]]}}}